缓释化疗系统在骨肉瘤治疗中的研究进展  

Research progress of slow-release chemotherapy system for osteosarcoma

作　　者：景义生 谢兴文 李宁 许伟[3] 李鼎鹏 黄委委 JING Yisheng;XIE Xingwen;LI Ning;XU Wei;LI Dingpeng;HUANG Weiwei(Clinical College of Traditional Chinese Medicine,Gansu University of Traditional Chinese Medicine,Lanzhou 730000,Gansu Province,China;Department of Geriatric Orthopedics and Department of Second Rehabilitation Orthopedics,Affiliated Hospital of Gansu University of Traditional Chinese Medicine,Lanzhou 730000,Gansu Province,China;Department of Bone and Soft Tissue Tumor,Gansu Provincial Hospital of Traditional Chinese Medicine,Lanzhou 730050,Gansu Province,China;Department of Orthopedics,Affiliated Hospital of Northwest University for Nationalities,Lanzhou 730000,Gansu Province,China)

机构地区：[1]甘肃中医药大学中医临床学院,甘肃兰州730000 [2]甘肃中医药大学附属医院老年骨科及康复骨二科,甘肃兰州730000 [3]甘肃省中医院骨与软组织肿瘤科,甘肃兰州730050 [4]西北民族大学附属医院骨科,甘肃兰州730000

出　　处：《肿瘤》2023年第12期984-992,共9页Tumor

基　　金：甘肃省拔尖领军人才项目

摘　　要：在过去20年中骨肉瘤标准治疗策略(新辅助化疗联合手术治疗及辅助化疗)对骨肉瘤患者生存期的改善已经趋于稳定,而缓(控)释药物递送系统的出现为骨肉瘤的治疗提供了新策略。目前,得益于纳米技术的发展,骨肉瘤缓释化疗技术有了长足进步,但缓释化疗体系的临床转化成为制约其发展的关键。基于此,本综述归纳整理了近年来骨肉瘤主要化疗药物甲氨蝶呤、多柔比星、顺铂及异环磷酰胺缓释系统的临床前研究进展,期望能明确骨肉瘤缓释化疗系统的安全性及有效性,促进骨肉瘤缓释化疗系统的临床转化。The improvement of survival of osteosarcoma patients by the standard treatment strategy of osteosarcoma(neoadjuvant chemotherapy+surgical treatment+adjuvant chemotherapy)has been stabilized in the past 20 years,and the emergence of the slow(controlled)-release drug delivery system has provided a new strategy for the treatment of osteosarcoma.At present,thanks to the development of nanotechnology,great progress had been made to the technology of slow-release chemotherapy for osteosarcoma in China,but the clinical translation of the slow-release chemotherapy system has become the key to constrain its development.Based on this,this review summarizes the preclinical research progress of the main chemotherapeutic agents for osteosarcoma,including methotrexate,doxorubicin,cisplatin,and isocyclophosphamide,in the recent years,with the expectation of clarifying the safety and efficacy of the slow-release chemotherapy system for osteosarcoma,and facilitating the clinical translation of the slow-release chemotherapy system for osteosarcoma.

关 键 词：骨肉瘤 缓释化疗 药物递送系统 缓释载体 智能响应系统 

分 类 号：R738.1[医药卫生—肿瘤]